- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms
- Interventions
- LY4257496, Standard of Care Anticancer Therapies, LY4257529
- Drug · Diagnostic Test
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 16
- States / cities
- Duarte, California • Santa Monica, California • Stanford, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 985–1008
of 2,481
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- Isatuximab, Iberdomide, Bortezomib, Dexamethesone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- Belinostat Injection, Pralatrexate Injection, CHOP, COP
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 10
- States / cities
- Clovis, California • Santa Monica, California • Aurora, Colorado + 7 more
- Conditions
- Liver Transplantation
- Interventions
- Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
- Drug
- Lead sponsor
- Enzon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- San Francisco, California • Omaha, Nebraska • New York, New York + 1 more
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor
- Interventions
- Abemaciclib, Irinotecan, Temozolomide, Dinutuximab, GM-CSF
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oakland, California + 9 more
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Interventions
- INCB052793, gemcitabine, nab-paclitaxel, dexamethasone, Carfilzomib, bortezomib, lenalidomide, azacitidine, pomalidomide, INCB050465, INCB039110
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 10 more
- Conditions
- Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
- Interventions
- GTB-5550
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Steatohepatitis
- Interventions
- Ontamalimab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Tucson, Arizona • Coronado, California + 11 more
- Conditions
- Peripheral Lung Tumor
- Interventions
- Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
- Combination Product
- Lead sponsor
- Impact Biotech Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced/Metastatic Clear Cell Renal Cell Carcinoma
- Interventions
- ALLO-316, ALLO-647, Fludarabine, Cyclophosphamide
- Genetic · Biological · Drug
- Lead sponsor
- Allogene Therapeutics
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms, ER Positive Breast Cancer, Cervical Cancers, Cervical Neoplasms, Cervical Carcinoma, Triple Negative Breast Cancer, Gynecologic Cancers, Gynecologic Neoplasm, Endometrial Cancer, Endometrial Neoplasm, Endometrial Carcinoma (EC), Fallopian Cancer, Ovarian Carcinoma, Ovarian Cancer, Ovarian Neoplasms, Prostate Cancers, Prostate Carcinoma, Solid Tumors, Neoplasms, Neoplasms by Site, Breast Diseases, Uterine Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms
- Interventions
- ATV-1601, ATV-1601 + Fulvestrant
- Drug · Combination Product
- Lead sponsor
- Atavistik Bio, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Lake Mary, Florida • Boston, Massachusetts + 2 more
- Conditions
- Tumors
- Interventions
- Lenvatinib, Pembrolizumab
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 50
- States / cities
- Anchorage, Alaska • Oro Valley, Arizona • Tucson, Arizona + 34 more
- Conditions
- Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Interventions
- Adagrasib, Pembrolizumab
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 220
- States / cities
- Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more
- Conditions
- Sepsis, Community Acquired Pneumonia (CAP)
- Interventions
- OPT101, Placebo
- Drug · Other
- Lead sponsor
- Op-T LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Human Immunodeficiency Virus (HIV) Infection
- Interventions
- HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2, Placebo
- Biological · Other
- Lead sponsor
- Hookipa Biotech GmbH
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Decatur, Georgia • Boston, Massachusetts + 1 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- LB-100
- Drug
- Lead sponsor
- Lixte Biotechnology Holdings, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
- Interventions
- BMS-986463
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Hackensack, New Jersey • Columbus, Ohio + 2 more
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Bortezomib, Dexamethasone, Pelareorep, Pembrolizumab
- Drug · Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Rivoceranib, Trifluridine/Tipiracil
- Drug
- Lead sponsor
- Elevar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • Chicago, Illinois • St Louis, Missouri + 1 more
- Conditions
- Open Angle Glaucoma
- Interventions
- 2.5mg ANX007, 5.0mg ANX007, Sham Procedure
- Biological · Other
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Newport Beach, California • Stanford, California
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
- Interventions
- P-PSMA-101 CAR-T cells, Rimiducid
- Biological · Drug
- Lead sponsor
- Poseida Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- Duarte, California • San Diego, California • San Francisco, California + 6 more
- Conditions
- HIV Infections
- Interventions
- MRKAd5 HIV-1 gag/pol/nef
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Rochester, New York • Nashville, Tennessee + 1 more
- Conditions
- Breast Cancer
- Interventions
- Vepdegestrant, Palbociclib
- Drug
- Lead sponsor
- Arvinas Estrogen Receptor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 16
- States / cities
- Palo Alto, California • San Francisco, California • Santa Monica, California + 12 more
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- PCI-32765
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • New Hyde Park, New York • New York, New York + 3 more